iCAD Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy (IORT) for Brain, Rectal, Head and Neck Tumor Treatment
05 avr. 2022 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., April 05, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that...
iCAD Highlights Breast Health AI Platform at the 2022 Healthcare Information and Management Systems Society (HIMSS) Meeting
14 mars 2022 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., March 14, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be...
iCAD Showcases Innovative Breast Health Solutions Platform at National Consortium of Breast Centers (NCoBC) 31st Annual Conference
10 mars 2022 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., March 10, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be...
iCAD to Present at the 32nd Annual Oppenheimer Healthcare Conference
09 mars 2022 11h21 HE
|
iCAD, Inc.
NASHUA, N.H., March 09, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the...
iCAD Among the First to Validate its AI Cancer Detection Solutions with the NVIDIA AI Enterprise Software Suite
02 mars 2022 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., March 02, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it is...
iCAD to Present at the 42nd Annual Cowen Health Care Conference
01 mars 2022 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., March 01, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the...
iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2021
28 févr. 2022 16h05 HE
|
iCAD, Inc.
Launched ProFound AI® Risk, the world’s first clinical decision support tool for short term breast cancer risk estimation Demonstrated compelling survival data for the use of Xoft® Brain IORT in...
iCAD to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28
14 févr. 2022 16h05 HE
|
iCAD, Inc.
NASHUA, N.H., Feb. 14, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it...
iCAD to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
08 févr. 2022 08h00 HE
|
iCAD, Inc.
NASHUA, N.H., Feb. 08, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company...
iCAD’s Breast AI Platform Earns U.S. Department of Defense Authorization to Operate
24 janv. 2022 14h25 HE
|
iCAD, Inc.
NASHUA, N.H., Jan. 24, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the...